title: Comparison of screening procedures for Mycobacterium tuberculosis infection among patients with inflammatory diseases.
abstract: OBJECTIVE
  To test if Mycobacterium tuberculosis screening results differ among patients with inflammatory disease depending on whether the QuantiFeron TB-Gold test (QFT) or tuberculin skin test (TST) is used; and to evaluate if a possible difference is influenced by the presence of risk factors or immunosuppression.
  
  
  METHODS
  The interferon-gamma response to in vitro stimulation of M. tuberculosis-specific antigens was measured with QFT and results were compared with TST. Associations to bacillus Calmette-Guerin (BCG) vaccination, risk factors, and immunosuppression were analyzed for both tests.
  
  
  RESULTS
  QFT and TST results were available for 294/302 and 241/302 patients, respectively; 234 had results from both tests. Twenty-one (7%) tested positive with QFT and 45 (19%) with TST. A positive QFT was associated with risk factors for M. tuberculosis infection: i.e., birth or upbringing in a TB-endemic area [risk ratio (RR) = 7.8, 95% CI 1.5-18.2, p < 0.001], previous TB treatment (RR 4.7, 95% CI 1.6-13.5, p = 0.005), and any latent TB infection risk factor (RR 4.7, 95% CI 2.1-11.0, p = 0.0002). Treatment with corticosteroids increased the risk for an inconclusive QFT result (RR 4.2, 95% CI 1.6-10.7, p = 0.04) and decreased the risk for a positive TST result (RR 0.4, 95% CI 0.1-1.0, p = 0.04). Agreement between the tests was low (kappa 0.2, 95% CI 0.02-0.3, p = 0.002).
  
  
  CONCLUSIONS
  The study documented a high degree of discordant positive QFT and TST results. A positive QFT was more closely associated with risk factors for M. tuberculosis infection than the TST. The use of corticosteroids affected test outcome by increasing the risk for an inconclusive QFT result and decreasing the risk for a positive TST result.
authors: Department of Epidemiology Research, Statens Serum Institut, Artillerivej 5, Copenhagen S, Denmark. bot@ssi.dk
authors: Bolette
authors: B
authors: Soborg
authors: Morten
authors: M
authors: Ruhwald
authors: Merete Lund
authors: ML
authors: Hetland
authors: Søren
authors: S
authors: Jacobsen
authors: Aase Bengaard
authors: AB
authors: Andersen
authors: Nils
authors: N
authors: Milman
authors: Vibeke Ostergaard
authors: VO
authors: Thomsen
authors: Dorte Vendelbo
authors: DV
authors: Jensen
authors: Anders
authors: A
authors: Koch
authors: Jan
authors: J
authors: Wohlfahrt
authors: Pernille
authors: P
authors: Ravn
mesh_terms: D000328:Adult; D000368:Aged; D001500:BCG Vaccine; D003955:Diagnostic Tests, Routine / Q000379:methods*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D008403:Mass Screening / Q000379:methods*; D008875:Middle Aged; D009169:Mycobacterium tuberculosis; D011237:Predictive Value of Tests; D012216:Rheumatic Diseases / Q000150:complications* / Q000188:drug therapy; D012307:Risk Factors; D012680:Sensitivity and Specificity; D014374:Tuberculin Test / Q000379:methods*; D014376:Tuberculosis / Q000175:diagnosis* / Q000453:epidemiology*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D001500:BCG Vaccine; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha